Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trialnews2026-01-08T13:00:44+00:00January 8th, 2026|Endpoints News|
Inside Doctronic’s experiment to allow AI to refill prescriptionsnews2026-01-08T13:00:33+00:00January 8th, 2026|Endpoints News|
Obesity biotech Alveus gains $160M for push into MariTide’s backyardnews2026-01-08T12:30:18+00:00January 8th, 2026|Endpoints News|
Tessera Therapeutics to lay off 90 employees, according to documentnews2026-01-08T12:29:39+00:00January 8th, 2026|Endpoints News|
GSK, Noetik sign cancer deal on AI virtual cell modelsnews2026-01-08T12:00:51+00:00January 8th, 2026|Endpoints News|
Boltz raises $28M seed to build open AI models in biologynews2026-01-08T12:00:51+00:00January 8th, 2026|Endpoints News|
Beacon Therapeutics adds $75M in push to succeed where J&J failed in vision treatmentnews2026-01-08T12:00:44+00:00January 8th, 2026|Endpoints News|
Parabilis gets $305M to tackle ‘undruggable’ proteinsnews2026-01-08T12:00:42+00:00January 8th, 2026|Endpoints News|
Vizgen raises $48M for push in spatial biology and multiomics toolsnews2026-01-08T12:00:41+00:00January 8th, 2026|Endpoints News|
French biotech Enodia gets €20.7M aided by Pfizer for protein degrader worknews2026-01-08T11:30:23+00:00January 8th, 2026|Endpoints News|
